November 29, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Salinomycin, Amitriptyline, Temozolomide, Berberine, Rosuvastatin and 17-DMAG (SATBRD) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 29/November/2017, 10.29 pm

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer […]
November 28, 2017

Natural product-derived therapy for Metastatic human tumors: Andrographolide, isolated from herb Andrographis Paniculata, decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via up regulation of its target gene, 28/November/2017, 11.14 pm

Introduction: What they say: A study from the State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen […]
November 25, 2017

Natural product-based combination therapy targeting cancer stem cells in Myeloid leukaemia (ML): A therapeutic mix encompassing Pseudolaric acid B, Rosiglitazone, Ivermectin, Dacogen (PRID) inhibits cytosolic aminotransferase BCAT1 expression, increases a-ketoglutarate levels, promotes degradation of HIF1a levels, increases DNA demethylase levels, promotes hypomethylation, increases the expression of tumor suppressor genes, inhibits leukaemia-initiating potential of AML cells, promotes differentiation of AML cells, and inhibits cancer progression in AML via up-regulation of its target gene, 25/November/2017, 4.13 pm

Introduction to what they say: A study from the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany; Division of Stem […]
November 23, 2017

Combinatorial therapy for prostate cancer:  A therapeutic mix encompassing Calcitriol, Mitoxantrone, Despiramine, 17-DMAG, Salinomycin, Lovastatin, and Jasmonate (CMDDSLJ) inhibits the expression of mTORC1 and its downstream target AMD1, dismantles mTORC1-AMD1 signaling network, decreases polyamine levels, and inhibits prostate cancer progression via up regualtion of its target gene, 23/November/2017, 12.15 pm

Introduction: What they say: A study from CIC bioGUNE (Center for Cooperative Research in Biosciences), Bizkaia Technology Park, 801 Building, 48160 Derio, Spain shows that “mTORC1-dependent AMD1 regulation sustains polyamine […]